LXR agonists for the treatment of atherosclerosis

Area of Science:

• Molecular Endocrinology
• Cardiovascular Research
• Metabolic Disease

Background:

• Liver X receptors (LXR) alpha/beta are nuclear receptors acting as intracellular sterol sensors.
• LXRs regulate genes involved in cholesterol homeostasis, including absorption, excretion, catabolism, and cellular efflux.
• LXR activation influences lipid metabolism in key organs like the small intestine, liver, and macrophages.

Purpose of the Study:

• To investigate the role of LXR agonists in cholesterol flux and atherosclerosis.
• To evaluate the therapeutic window of synthetic dual LXR alpha/beta agonists.
• To explore the potential of subtype-selective LXR agonists or modulators to separate anti-atherosclerotic and lipogenic effects.

Main Methods:

• Review of LXR pathway mechanisms and gene expression regulation.
• Analysis of studies using synthetic dual LXR alpha/beta agonists in animal models.
• Examination of findings related to atherosclerosis reduction and lipogenic effects.

Main Results:

• LXR agonists coordinate gene expression to increase peripheral cholesterol flux to the liver for biliary excretion.
• Synthetic dual LXR alpha/beta agonists demonstrated efficacy in decreasing atherosclerosis in mouse models.
• Upregulation of lipogenic target genes and elevated triglycerides were observed in rodents, indicating a narrow therapeutic window.

Conclusions:

• Dual LXR agonists offer a mechanism to enhance cholesterol clearance but are limited by adverse metabolic effects.
• The dissociation of anti-atherosclerotic and lipogenic actions is a critical goal for therapeutic development.
• LXR subtype-selective agonists or modulators represent a promising strategy to optimize LXR-based therapies.